A single night in hypoxia either with or without ketone ester ingestion reduces sleep quality without impacting next day

exercise performance

1	Myrthe Stalmans ¹ , Domen Tominec ² , Robberechts Ruben ¹ , Wout Lauriks ¹ , Monique
2	Ramaekers ¹ , Tadej Debevec ^{2,3} , Chiel Poffé ^{1,4} #
3	¹ Exercise Physiology Research Group, Department of Movement Sciences, KU Leuven,
4	Leuven, Belgium
5	² Faculty of Sport, University of Ljubljana, Ljubljana, Slovenia
	³ Department of Automatics, Biocybernetics and Robotics, Jožef Stefan Institute, Ljubljana,
	Slovenia
	⁴ REVAL – Rehabilitation Research Center, Faculty of Rehabilitation Sciences, Hasselt
	University, Diepenbeek, Belgium

- 6 **#, Correspondence:** Chiel Poffé, REVAL Rehabilitation Research Center, Faculty of
- 7 Rehabilitation Sciences, Hasselt University, Wetenschapspark 7, 3590 Diepenbeek, Belgium
- 8 Email: <u>chiel.poffe@uhasselt.be</u>
- 9 Running head: Ketones do not impact sleep in hypoxia
- 10 Keywords: ketone; sleep; recovery; oxygen saturation; exercise performance; hypoxia

11 ABSTRACT

12 **Background:** Sleeping at (simulated) altitude is highly common in athletes as an integral 13 part of altitude training camps or sport competitions. However, it is also often feared due to 14 proclaimed negative effects on sleep quality, thereby potentially hampering exercise recovery 15 and next-day exercise performance. We recently showed that ketone ester (KE) ingestion 16 beneficially impacted sleep following strenuous, late evening exercise in normoxia, and 17 alleviated hypoxemia. Therefore, we hypothesized that KE ingestion may be an effective 18 strategy to attenuate hypox(em)ia-induced sleep dysregulations. Methods: Eleven healthy, 19 male participants completed three experimental sessions including normoxic training and 20 subsequent sleep in normoxia or at a simulated altitude of 3,000m while receiving either KE 21 or placebo post-exercise and pre-sleep. Sleep was evaluated using polysomnography, while 22 next-day exercise performance was assessed through a 30-min all-out time trial (TT_{30}) . 23 Physiological measurements included oxygen status, heart rate variability, ventilatory 24 parameters, blood acid-base balance and capillary blood gases. **Results:** Hypoxia caused a 25 \sim 3% drop in sleep efficiency, established through a doubled wakefulness after sleep onset and 26 a $\sim 22\%$ reduction in slow wave sleep. KE ingestion alleviated the gradual drop in SpO₂ 27 throughout the first part of the night, but did not alter hypoxia-induced sleep dysregulations. 28 Neither KE, nor nocturnal hypoxia affected TT_{30} performance, but nocturnal hypoxia 29 hampered heart rate recovery following $TT_{30'}$. Conclusion: We observed that sleeping at 30 3,000m altitude already impairs sleep efficiency. Although this hypoxia-induced sleep 31 disruption was too subtle to limit exercise performance, we for the first time indicate that 32 sleeping at altitude impairs next-day exercise recovery. KE alleviated nocturnal hypoxemia 33 whenever SpO_2 values dropped below ~85%, but this did not translate into improved sleep or 34 next-day exercise performance.

35 **Word count**: 273

36 INTRODUCTION

37 Sleeping at (simulated) altitude is highly common in athletes as an integral part of 38 altitude training camps. However, athletes are also often enforced to sleep at altitude during 39 major sport competitions such as grand tours in cycling, Olympic Games, multi-day 40 ultrarunning races or mountaineering expeditions. During altitude training camps, nocturnal 41 hypoxic exposure is considered essential for inducing favorable physiological adaptations in 42 the longer term such as increased hemoglobin mass and maximal oxygen consumption rates 43 which may ultimately improve endurance exercise performance (1). Conversely, sleeping at 44 altitude is also often feared by athletes – especially during competitions – due to proclaimed 45 negative effects of hypoxia on sleep quality which may in turn hamper exercise recovery and 46 next-day exercise performance.

47 In this respect, studies generally observed that a single night at (simulated) altitudes 48 above 2,000 m impairs sleep quality (2-10). This is evidenced by decreases in either rapid eye 49 movement (REM) or slow wave sleep (SWS), or an increase in wakefulness during the night. 50 Methodological heterogeneity and contradictory findings, however, hinder unequivocal 51 conclusions and a clear rationale. In general, REM sleep is unaffected at altitudes up to 52 3,800m (2, 4, 6, 7, 11–13) but decreases up to 40% at altitudes starting from 4,000m (3, 5, 9, 53 10). Data on SWS is much more equivocal with some studies reporting no changes at altitudes 54 up to 3,800m (7, 11, 12), while other studies reported decreases from $\sim 20-45\%$ at altitudes 55 between 2,000 and 4,300m (2, 5, 6, 9, 13). This is generally accompanied by an increased 56 wakefulness after sleep onset (WASO) (3-7, 9). Conversely, sleep efficiency typically 57 remains unaffected by altitudes of up to 4,000m (2–4, 6, 7, 11–13), but decreases by 10-20% 58 at 4,000m (3, 13) and higher (9).

4

59 Sleep disturbances may have both direct and indirect implications for athletic performance. 60 This is evidenced by studies showing that a single night of restricted sleep (i.e., sleep time 61 reduction of 2-4h) increases cardiac stress during and after exercise on the next day (14). 62 Furthermore, ~5 days of disturbed sleep has been shown to suppress myofibrillar and 63 sarcoplasmic protein synthesis rates (15, 16), to impair insulin sensitivity (17), and to reduce 64 mitochondrial respiratory function (16). Although some studies reported no impact of sleep 65 restriction down to 2h per night on next day exercise performance (14, 18), other studies 66 indicated that a single night of \sim 2-3h sleep deprivation is sufficient to decrease 6s peak 67 cycling power output and both 3 and 20 km cycling time-trial performance (19, 20). 68 Nevertheless, it is currently unknown if the more subtle differences in sleep quality and 69 quantity that are expected to occur upon a single night in hypoxia also impair next day 70 exercise performance.

71 The precise underlying mechanisms of hypoxia-induced sleep impairments are currently 72 unknown. Yet, they are most likely caused by hypoxemia (8, 12, 21, 22). Interestingly, we 73 previously showed that increasing blood ketone bodies (KB), via oral ketone ester (KE) 74 ingestion, attenuated the drop in blood (as well as muscle and brain) oxygenation after 3-4h in 75 hypoxia (23, 24). Furthermore, we identified that KE intake post-exercise and pre-sleep 76 beneficially impacted sleep following strenuous, late evening exercise in normoxic 77 conditions. This was evidenced by an inhibition of late evening exercise-induced decreases in 78 REM sleep and WASO, and a 2% improvement in sleep efficiency (25).

These data indicate that pre-sleep KE ingestion may be an effective strategy to attenuate hypox(em)ia-induced sleep dysregulations. Against this background, this study aims to identify the impact of a single night in hypoxia on (i) nocturnal sleep measured using golden standard polysomnography, and (ii) next day exercise performance, and to (iii) explore the

- 83 potential of KE supplementation to counteract potential performance or sleep dysregulations
- 84 under these conditions.

85 METHODS

86 Ethical approval and participants. This research was registered at www.clinicaltrials.gov 87 (NCT06060093) and approved by the Ethics Committee Research UZ/KU Leuven 88 (B3222022001041). Potential participants were medically screened and provided written 89 informed consents. Candidates' sleep quality was screened using the Pittsburgh Sleep Quality 90 Index (PSQI) in order to guarantee adequate baseline sleep quality as defined by the National 91 Sleep Foundation (i.e., sleep efficiency above 85%). Participants working in late-night shifts, 92 as well as extreme morning and evening chronotypes as determined by the Horne-Östberg 93 questionnaire were excluded. All thirteen healthy, male participants that were included 94 reported good sleep quality and no indications for sleep disorders (PSQI score <5). None of 95 them showed indications for psychological or neurological disorders, such as depression 96 (Beck's Depression questionnaire) or anxiety (Beck's Anxiety questionnaire). All participants 97 were active in cycling, endurance running or triathlon. Further exclusion criteria included 98 smoking, exposure to altitudes >1,500m during the 3 months preceding the study or a history 99 of altitude-sensitive pathologies. From the thirteen participants that were initially included, 100 one dropped out due to a Covid-19 infection and another one was excluded from the data 101 analyses due to a baseline sleep quality drastically below the predefined inclusion criteria 102 (i.e., sleep efficiency of 78%). Therefore, data analyses were performed on 11 participants 103 [age: 24 ± 4 yr; height: 181.3 ± 7.5 m; body mass: 73.2 ± 9.2 kg; physical activity: 8 ± 3 h.week⁻¹, $V \square O_2$ max: 61.5 ± 8.8 mL.kg⁻¹.min⁻¹ (mean ± SD)]. 104

105 *General study design.* This randomized, double-blind, placebo-controlled, cross-over 106 study consisted of three experimental sessions. These sessions were designed to mimic a live-107 high, train-low setup, and all included an identical training session in normoxia whereafter 108 participants either spend the night in (i) normoxia (N_{PL}) or (ii) normobaric hypoxia (~3,000m 109 simulated altitude) while receiving a placebo (H_{PL}), or in (iii) hypoxia while receiving KE

7

110 (H_{KF} , Fig. 1). Following the night in either hypoxia or normoxia, participants performed an 111 all-out 30min time-trial (TT_{30}) to evaluate exercise performance. Physiological measurements 112 were performed at rest throughout both days of the protocol. This design allowed us to 113 evaluate both (i) the impact of sleeping in hypoxia vs. normoxia, and (ii) the potential of KE 114 to improve sleep in hypoxia. All experimental sessions were conducted in a normobaric 115 hypoxic facility (Van Amerongen CA Technology, Tiel, The Netherlands) at the Bakala 116 Athletic Performance Center (Leuven, Belgium). The experimental sessions were separated 117 by a one-week wash-out period, and experimental protocols and timings were identical for all 118 three sessions.

119 Preliminary testing and familiarization sessions. Two weeks before the first 120 experimental session, participants performed a familiarization session consisting of a graded 121 exercise test on a cycling ergometer (Avantronic Cyclus II, Leipzig, Germany) to assess both 122 their lactate threshold (LT) and maximal oxygen uptake rate ($V \square O_2 max$). For the LT 123 determination, initial workload was set at 70W and increased by 40W per 8min. Capillary 124 blood samples were obtained every 4min for determination of blood lactate concentration 125 (Lactate Pro2; Arkray, Amstelveen, The Netherlands), with LT being defined as the lowest 126 workload provoking a 1 mM blood [lactate] increase within the same stage (25-27). After 127 15min of active recovery at 70W, participants started a second incremental cycling test 128 (100W + 25W/30sec) until volitional exhaustion. Throughout this test, oxygen consumption 129 $(V \square O_2)$ and carbon dioxide production $(V \square CO_2)$ rates were measured continuously using 130 indirect calorimetry (Cortex Metalyzer 3B, Cortex, Leipzig, Germany), and $V \square O_2$ max was 131 calculated as the highest $V \square O_2$ over a 30-sec period.

In the 2 weeks before the first experimental session, participants performed the full experimental protocol twice in normoxia to get accustomed to the experimental procedures, exercise protocols, and sleeping facility. Starting from the first familiarization session,

8

135 participants were asked to maintain a stable sleep schedule until the final experimental 136 session. This included the requirement to sleep 7-9h per night, with bed-time between 10-12 137 PM and wake-time between 6-8 AM. Compliance to a stable sleep-wake schedule was 138 assessed throughout the entire study period via a sleep diary and actigraphy (Actigraph 139 wGT3X-BT, ActiGraph LLC, Pensacola, Florida, US). Moreover, sleep quality of the night 140 prior to each experimental session was also assessed using the St. Mary's Sleep questionnaire. 141 *Experimental sessions.* After waking up at their individually predetermined time, 142 participants arrived in a fasted state between 7.00 and 9.00 AM at the testing facility (exact 143 timings were replicated for each session). 2.5h after consuming a standardized breakfast (see 144 Dietary standardization below), they performed a 2-h morning endurance training session 145 (ET_{120}) on a cycling ergometer (Tacx Neo Smart, Wassenaar, The Netherlands). ET_{120} 146 consisted of eight consecutive 15-min intervals with workload alternating between 60% and 147 80% of LT. 1.5h after lunch time, participants completed an 80-min high intensity interval 148 training (HIIT₈₀) on a cycling ergometer (Avantronic Cyclus II, Leipzig, Germany). HIIT₈₀, 149 consisted of a 10-min warm up at 70% of LT, followed by 10 repetitions of 3min at 120% of 150 LT interspersed by 4min active recovery at 50% of LT. Thirty minutes after HIIT_{80'} (~5h 151 before sleep-time), participants entered their individual 'hotel room' that was set at either 152 hypoxia (H_{PL} and H_{KE} ; F_IO_2 : 14.5% O_2 , P_IO_2 : ~110 mmHg, ~3,000m simulated altitude) or 153 normoxia (N_{PI}; F_IO₂: 20.9% O₂, P_IO₂: ~160 mmHg). Subsequently participants resided for 154 16h under these environmental conditions, with sleep being measured in each condition using 155 polysomnography (PSG). Following 16h of hypoxia/normoxia, participants returned to 156 normoxia and exercise performance was assessed 3.5h later by means of an all-out 30-min 157 time trial (TT_{30}) . In addition, physiological measurements were performed at rest at the 158 following timepoints: (i) before ET_{120} (baseline, 0h), (ii) after 2h in hypoxia or equivalent in 159 normoxia (+10h), (iii) immediately upon waking up (+23h), and (iv) 2h after returning to

9

160 normoxia (+27h). These measurements included determination of heart rate (HR), heart rate

- 161 variability (HRV), ventilatory parameters, and blood, brain and skeletal muscle oxygenation.
- 162

163 Supplementation protocol. In a randomized order, participants received 25g of either a 164 ketone ester $[H_{KE}, 96\% (R)-3-hydroxybutyl (R)-3-hydroxybutyrate, KetoneAid Inc., Falls$ 165 Church, Virginia, USA] or a placebo (N_{PL} and H_{PL} details below) supplement immediately 166 after (i) $ET_{120'}$ and (ii) $HIIT_{80'}$, (iii) after 1.5h in hypoxia (or equivalent in normoxia), and (iv) 167 30min before sleep. Hence, in H_{KE} participants received a total dose of 100g ketone ester $(1.39 \pm 0.17 \text{ g} \cdot \text{kg}^{-1} \text{ body weight})$ in order to intermittently elevate blood ketone bodies post-168 169 exercise and throughout the first part of the night. In N_{PL} and H_{PL} , participants received a total 170 of 100g of a taste and viscosity matched, inert placebo consisting of 12.5% w/v collagen (6d 171 Sports Nutrition, Oudenaarde, Belgium) and 1 mM bitter sucrose octaacetate (Sigma-Aldrich, 172 Bornem, Belgium) dissolved in water. In total, caloric intake via the KE supplements was 173 ~700 kcal vs. ~0 kcal for the placebo supplements. Randomization was performed by a 174 researcher who was otherwise not involved in the study.

175 Dietary standardization. The evening before each experimental session, participants 176 consumed a standardized carbohydrate-rich dinner at home (~5,600 kJ; 69% carbohydrate, 177 16% fat, 15% protein). Water consumption was allowed *ad libitum* until arrival at the facility 178 the next morning, and was replicated for each session. After participants arrived at the testing 179 facility in a fasted state, they consumed a standardized breakfast (~4,200 kJ; 68% 180 carbohydrate, 21% fat, and 11% protein). Subsequently participants received a carbohydrate-181 rich snack (~660 kJ; 92% carbohydrate, 3% fat, and 5% protein) 1h before ET₁₂₀, and 182 received 60g carbohydrates per hour during ET_{120} via isotonic drinks and carbohydrate-rich 183 snacks (6d Sports Nutrition, Oudenaarde, Belgium). A light lunch (~4,150 kJ; 74% 184 carbohydrate, 25% fat, and 14% protein) was provided 1.5h before HIIT₈₀, and participants

10

185 received a high-carbohydrate, high-protein recovery shake (60g carbohydrate, 30g protein, 6d 186 Sports Nutrition, Oudenaarde, Belgium) immediately after HIIT₈₀. After 30min in 187 hypoxia/normoxia, a standardized dinner (~3,250 kJ; 69% carbohydrate, 5% fat, and 26% 188 protein) was served while participants received a light snack (~1,700 kJ of which 69 % 189 carbohydrates, 15 % protein, 16 % fat) 2h before sleep time in order to prevent participants 190 from going to bed hungry. Hence, total caloric intake on the first day – excluding the KE 191 supplements – was ~3,590 kJ. The next morning, participants received an identical breakfast 192 as on the first day, and received a carbohydrate-rich snack (cfr. before ET_{120}) 30min before 193 $TT_{30'}$.

194

195 *Nocturnal measurements.*

196 Polysomnography (PSG). A digital amplifier (V-amp, Brain Products, Gilching, 197 Germany) was used to record sleep quality and quantity during the experimental sessions, and 198 data were digitized at a sampling rate of 1000 Hz. According to the international 10 - 20199 system, electroencephalographic (EEG) recordings were made from Fz, Cz, Pz, Oz, C3, C4, 200 A1, and A2 where the A2 electrode served as the reference electrode and A1 as a backup 201 reference. A ground electrode was positioned in the middle of the forehead. Eye movements 202 (vertical/horizontal) were recorded with electrooculographic (EOG) electrodes above and 203 under the right eye and with electrodes attached to the outer cantus of both eyes. A 0.1 Hz low 204 cut-off filter and a 30 Hz high cut-off filter were applied to both EEG and EOG data. 205 Submental muscle tone and movements were assessed with a electromyogram (EMG) of the 206 chin, recorded with a low cut-off filter of 10 Hz and a high cut-off filter of 200 Hz. Electrical 207 noise was filtered out with a 50 Hz notch filter. A blinded, independent, certified sleep 208 technician (Sleep Well PSG, Canada) visually scored night recordings following the 209 Rechtschaffen & Kales guidelines, in conjunction with the AASM guidelines, in 30 s epochs.

11

210 A 0.3 - 35 Hz, 0.3 - 30 Hz, and a 10 - 100 Hz bandpass filter was used for EEG, EOG and 211 EMG signals, respectively. The assessed sleep variables were: (i) total sleep time, (ii) WASO, 212 (iii) total NREM and REM sleep, (iv) total N1, N2, and REM and SWS sleep, (v) sleep onset, 213 sleep onset to N2, SWS, and REM sleep, (vi) sleep efficiency (total sleep time/time in bed), 214 and (vii) amount of awakenings. 215 Sleep event detection. EEG data were preprocessed in BrainVision Analyzer (Brain 216 Products GmbH, Gilching, Germany). After applying a 0.1 - 30 Hz bandpass filter, data were 217 transferred to a Python environment (version 3.10.5). Detection of both 'slow waves' and 218 'sleep spindles' was performed according to previously described guidelines (28). For each 219 channel, the densities of slow waves and sleep spindles were averaged across the channels for 220 N2 and SWS phases. 221 Oxygen saturation and HR. During the participants' registered sleep time, blood oxygen 222 saturation (SpO₂) and HR were continuously assessed using pulse oximetry (Nellcor PM10N, 223 Medtronic, Minneapolis, USA). These data were used to calculate both average and minimal

229

224

225

226

227

228

Resting measurements. All resting measurements were performed by the same trained researcher. Measurements were performed throughout a 10min time-window and with the participants being in supine position for at least 10min before the start of the first measurement. Data for all parameters are presented as the average values of the last minute.

HR, the minimal SpO_2 , the average nocturnal SpO_2 both over the entire night, as well as

within 10% epochs of the night. Furthermore, variation in SpO_2 was assessed through a

coefficient of variation (CV) for every hour ($CV_i = SD_i / mean_i$ with i = the hour of the night)

in agreement with an earlier study (29). CV_i was calculated given earlier evidence that

periodic breathing causes fluctuations in nocturnal oxygen saturation in preterm infants (30).

12

234 Blood and tissue oxygenation status. Blood oxygen saturation (SpO₂) was assessed using 235 a pulse oximeter (Nellcor PM10N, Medtronic, Minneapolis, USA) with an infrared sensor 236 placed ~2 cm above the left eyebrow and with sampling frequency set at 2 Hz. Cerebral and 237 skeletal muscle oxygenation status were assessed by means of tissue oxygenation index (cTOI 238 and mTOI, resp.) using near infrared spectroscopy (NIRS). The probes of a NIRO-200 239 spectrometer (Hamamatsu, Japan) were attached ~2 cm above the right eyebrow (cerebral 240 oxygenation) and centrally on the belly of the right *m. vastus lateralis* (skeletal muscle 241 oxygenation). A constant penetration depth of ~ 2 cm into the muscle/brain tissue was ensured 242 by inserting the emitter and detector probes in a dark-colored rubber spacer, maintaining a 243 fixed interoptode distance of 4 cm. These spacers were attached to the participants using an 244 elastic non-transparent bandage and double-sided adhesive tape to prevent displacement or 245 interference from external light. Before each experimental session, the participants' skin was 246 shaved and cleaned to exclude any signal disturbance by hair or impurities. Moreover, exact 247 inter-session replication was guaranteed by marking the contour lines of the rubber spacer on 248 the skin. Participants were asked to preserve and refresh these marks during the washout 249 period in order to maintain this position during the following sessions. After experimental 250 data collection, NIRS data were preprocessed (Matlab R2023a, The Mathworks, Natick, MA) 251 over 1-min long time chunks using a fourth-order Butterworth filter with a cut-off frequency 252 of 0.05 Hz (24).

Heart rate and heart rate variability. Resting HR and RR-peak intervals were measured using a Polar H10 (Polar, Kempele, Finland). HRV was analyzed by using the percentage of adjacent NN intervals that differ by more than 50 ms (pNN50), the root mean square of successive differences (RMSSD), and absolute power of the high-frequency band (HF) using Kubios (Kubios HRV Standard 3.5.0, Kubios Oy, Kuopio, Finland).

13

258 *Ventilatory gas exchange measurements.* Indirect calorimetry (Cortex Metalyzer 3b, 259 Leipzig, Germany) was used to measure breath-by-breath gas exchange data [*i.e.*, minute 260 ventilation ($V \square E$), oxygen uptake rate ($V \square O_2$) and carbon dioxide production rate 261 ($V \square CO_2$)].

262

263 **Exercise performance.** After returning to normoxia on the second day, participants 264 performed TT_{30} , which was preceded by a 15-min warm-up at 70% of LT on a cycling 265 ergometer (Avantronic Cyclus II, Leipzig, Germany). Participants were instructed to achieve 266 an average power output as high as possible and were allowed to voluntary change the applied 267 workload every 5min in the initial 25min, and every 1min during the final 5min. The starting 268 workload was determined during the familiarization sessions, where initial power in the first 269 session was set at the LT and in the second as the average power output of the first TT_{30} . In 270 turn, the average of the second TT_{30} , functioned as the starting workload of both experimental 271 $TT_{30'}$.

272

273 *Capillary blood, urine sampling and analyses.*

274 Capillary samples. Before breakfast (baseline, 0h), thirty min after every supplement 275 ingestion (+5.5h, +9h and +11h and +13h), and immediately upon waking up on the second 276 morning (+23h), a capillary blood sample was obtained for immediate determination of D- β -277 hydroxybutyrate (GlucoMen Areo 2K-meter with ß-ketone sensor strips, A. Menarini 278 Diagnostics, Firenze, Italy). In addition, 70 µl capillary blood was collected from a hyperemic 279 earlobe into a capillary tube (safeCLINITUBE, Radiometer Medical ApS, Copenhagen, 280 Denmark) before every resting measurement (baseline, +10h, +23h and +27h) and 281 immediately before sleep (+13h). After immediate mixing for 10sec, samples were analyzed

14

for acid-base balance, p50, and pCO₂ (ABL90 FLEX analyzer, Radiometer Medical ApS,
Copenhagen, Denmark).

Urine samples. Immediately before sleep time, participants emptied their bladder and nocturnal urine was collected until wake-up in urine flasks prepared with 10 mL hydrochloric acid. A small volume (~10 mL) of urine was frozen (-80 °C) for subsequent analyses of adrenaline, noradrenaline, and dopamine using a commercially available ELISA kit (BA E-

288 6600, LDN, Nordhorn, Germany) within 4 weeks after the final experimental session.

289

290 Statistical analyses. All statistical analyses were performed in GraphPad Prism version 291 10.1.2 (GraphPad Software, La Jolla, CA, USA). Prior to statistical testing, normal 292 distribution of the data was evaluated and confirmed with the D'Agostino-Pearson normality 293 test for SpO₂ and HR during the night as well as power output and HR during TT_{15} . One way 294 analysis of variance (ANOVA) was used to evaluate differences between conditions for 295 measurements obtained at a single time point during each session. Data collected at multiple 296 time points within a given experimental session were analyzed by means of a two-way 297 repeated measures ANOVA. A Geisser-Greenhouse correction was applied whenever the 298 assumption of sphericity was violated (Mauchly's test, JASP version 0.18.1, JASP Team, 299 Amsterdam, The Netherlands). In case of a significant main or interaction effect, *post-hoc* 300 analyses were performed using Šidák's correction. When applicable, reported p-values refer 301 to these post-hoc analyses and otherwise, p-values for main effects were included. All data are 302 presented as mean \pm SD and statistical significance was defined as p < 0.05. An a-priori 303 sample size calculation was performed based on the effect size of KE on sleep efficiency (i.e., 304 primary outcome of the current study) that was derived from our previous study investigating 305 the effect of KE during sleep in normoxia (25). Power analysis (G*Power version 3.1.9.7) 306 indicated that a sample size of 6 per condition is required to establish a significant effect on

- 307 sleep efficiency (effect size η_p^2 : 0.45; α error: 0.05; power: 0.80; correlation among repeated
- 308 measures: 0.5; nonsphericity correction: 1; ANOVA: repeated measures, within factors).

309 **RESULTS**

310Blood βHB concentrations. A time x condition effect was observed for blood [βHB] (p311< 0.001, Fig. 2). Baseline concentrations were low (~0.4 mM) in all conditions, and</td>312concentrations remained low (~0.4-0.5 mM) throughout the entire protocol in N_{PL} and H_{PL}.313Conversely, blood [βHB] consistently increased to 2-3 mM (range: 1.4 to 4.7 mM) thirty min314after ingestion of each KE supplement. Upon waking up the second day of the protocol, blood315[βHB] had returned to baseline values in all conditions.

316

317 *Sleep architecture.* Time in bed was kept constant for a given subject across all conditions and was on average 512 \pm 25min. Compared to N_{PL}, H_{PL} decreased sleep 318 319 efficiency by 3% (p = 0.037, Fig. 3a). This was mediated by a doubling (+ ~17min) of WASO 320 (p = 0.049, Fig. 3b), increased number of arousals (p = 0.027, Fig. 3c) while sleep onset 321 latency (p = 0.316, Fig. 3d), and latencies of N2, SWS and REM phases remained unaffected 322 (all p > 0.29, data not shown). The reduced sleep efficiency in H_{PL} vs. N_{PL} was accompanied 323 by a ~22% reduction in SWS (p = 0.002, Fig. 3e), and a ~39% increase in N1 duration (p =324 0.034, Fig. 3f), while N2 phase and REM sleep duration remained unaffected (p > 0.271, Fig. 325 3g-h, resp.). KE did not affect any of the hypoxia-induced dysregulations as all parameters 326 were similar between H_{PL} and H_{KE} (all p > 0.340). Densities of both sleep spindles and slow 327 waves during N2 (p = 0.082 and p = 0.307, resp.) and SWS (p = 0.752 and p = 0.782, resp.) 328 were unaffected throughout the experimental sessions (data not shown).

329

330 Subjective sleep quality. A main effect was observed for the following questions in the 331 St. Mary's sleep questionnaire; 'How deep was your sleep?' (N_{PL} : 5 ± 1, H_{PL} : 4 ± 1, H_{KE} : 4 ± 332 1; p = 0.007), 'How many times did you wake up?' (N_{PL} : 3 ± 1, H_{PL} : 4 ± 2, H_{KE} : 4 ± 1; p = 333 0.007), 'How clear-headed did you feel after getting up this morning?' (N_{PL} : 4 ± 1, H_{PL} : 2 ±

334	1, H_{KE} : 3 ± 1; p = < 0.001), 'How satisfied were you with last night's sleep?' (N_{PL} : 4 ± 1, H_{PL} :
335	3 ± 1 , H_{KE} : 3 ± 1 ; $p = 0.015$). Post-hoc analyses indicated that, compared to N_{PL} , participants
336	in H_{PL} perceived that they slept less deep, woke up more times during the night, felt less clear-
337	headed after getting up and were less satisfied with their night's sleep. Except for a more
338	clear-headed feeling upon waking up in H_{KE} (p = 0.012 vs. H_{PL}), no differences were observed
339	between H_{PL} and H_{KE} . No effects were observed for the questions 'How much sleep did you
340	have last night?' (N _{PL} : 8 ± 1 , H _{PL} : 7 ± 1 , H _{KE} : 8 ± 1 ; $p = 0.099$), 'How much sleep did you
341	have during the day, yesterday?' (N _{PL} : 0 ± 0 , H _{PL} : 0 ± 0 , H _{KE} : 0 ± 0), 'How well did you sleep
342	last night?', (N _{PL} : 4 \pm 1, H _{PL} : 3 \pm 1, H _{KE} : 3 \pm 1; p = 0.051), 'Were you troubled by waking
343	early and being unable to get off to sleep again?', (N _{PL} : 1 \pm 1, H _{PL} : 0 \pm 1, H _{KE} : 1 \pm 0; p =
344	0.123) and 'How much difficulty did you have in getting off to sleep last night?', (N _{PL} : 1 ± 1 ,
345	H_{PL} : 2 ± 1, H_{KE} : 1 ± 0; p = 0.224)

346

347 Nocturnal oxygen saturation and heart rate. At the start of the night, SpO₂ was 9% 348 lower in H_{PL} compared to N_{PL} (p < 0.001, Fig. 4a). Throughout the first half of the night, 349 SpO_2 gradually decreased in all conditions, reaching minimal SpO_2 levels after ~220min in bed or ~44% of sleep for all conditions (p = 0.954 and p = 0.921, resp., data not shown). Due 350 351 to both lower baseline values and a steeper reduction throughout the night in H_{PL} vs. N_{PL} , 352 minimal and average SpO₂ were respectively 20 and 13% lower in H_{PL} compared to N_{PL} ($p < 10^{-10}$ 353 0.001, Fig. 4b-c). KE ingestion alleviated the gradual drop in SpO₂ throughout the first part of 354 the night (Fig. 4a). Hence, SpO_2 after 40% of the night, as well as minimal SpO_2 were both 355 4% higher in H_{KE} vs. H_{PL} (p = 0.029 and p = 0.048, Fig. 4a and Fig. 4b, resp.). Conversely, 356 average nocturnal SpO₂ was similar between H_{KE} and H_{PL} (p = 0.519 vs. H_{PL} , Fig. 4c). 357 HPL strongly increased the CV of SpO2 during all hours of the night compared to NPL (p

358 < 0.002, Fig. 4d). This increase in CV was attenuated by KE ingestion during the 2nd hour of

18

the night (p = 0.008 *vs.* H_{PL}), but not at any of the other timepoints. Compared to N_{PL}, H_{PL} increased minimal and average nocturnal HR by respectively ~10% and ~20% (p = 0.008 and p < 0.001 vs. N_{PL}, resp, Fig. 4e-f). KE further increased minimal nocturnal HR by ~8% (p = 0.019 for H_{KE} *vs.* H_{PL}), and tended to further elevate average nocturnal HR (p = 0.079 for H_{KE} *vs.* H_{PL}).

364

365 *Exercise performance.* Mean power output during TT_{30} was similar between all 366 conditions at ~285W [p = 0.454, confidence interval (CI): -5 to +9 W for N_{PL} *vs.* H_{PL} and -9 367 to +12 for H_{KE} *vs.* HPL, Fig. 5a,b). Also average HR during TT_{30} (Fig. 5c) was similar 368 between all conditions (p = 0.251). However, after 5 min of passive recovery, participants HR 369 remained ~6-9 bpm higher in H_{PL} and H_{KE} compared to N_{PL} (p < 0.001, Fig. 5d)

370

371 **Resting measurements** – oxygen status, heart rate and heart rate variability. A time x 372 condition effect was detected for SpO₂ (p < 0.001, Table 1). Compared to N_{PL}, SpO₂ dropped 373 to a similar extent in H_{PL} and H_{KE} both at +10h ($p < 0.001 vs. N_{PL}$) and +23h (p < 0.001 vs.374 N_{PL}). Conversely, both cTOI and mTOI remained stable at respectively ~73% and ~67% in all 375 experimental conditions (data not shown). For HR, a time x condition effect was found (p < p376 0.001, Table 1). Post-hoc analyses indicated that HR was ~14% higher in H_{PL} vs. N_{PL} at +10h 377 (p < 0.001), and even ~20% higher at +23h (p < 0.001). KE ingestion further increased resting 378 HR at +10h (p $< 0.001 vs. H_{PL}$). An interaction effect was observed for all measured HRV 379 indices (pNN50, p = 0.002; RMSSD, p < 0.001; HF, p = 0.005; Table 1). Compared to N_{PL}, 380 H_{PL} lowered pNN50, RMSSD and HF at +10h, while at +23h only pNN50 and RMSSD were 381 decreased. KE did not alter the impact on RMSSD, but lowered pNN50 and HF at +23h 382 compared to H_{PL}.

19

384	Resting measurements – acid-base balance, blood gasses and ventilatory parameters.
385	Blood pH, p50, pCO ₂ , as well as ventilatory parameters were similar between all conditions at
386	baseline (Table 2). Compared to N_{PL} , H_{PL} increased blood pH at +10h and +23h but not at
387	+27h, while pCO ₂ was decreased at all timepoints. Conversely, p50 remained similar between
388	N_{PL} and H_{PL} at all timepoints. Relative to H_{PL} , H_{KE} caused a slight acidosis at +10h which was
389	accompanied by a KE-induced reduction in pCO ₂ , and an increase in p50. Each of these KE-
390	induced alterations were again normalized at +23h and +27h. Irrespective of the experimental
391	condition, V \Box E was similar at baseline (11.5 ± 0.2 L.min ⁻¹), increased at +10h (13.1 ± 0.2
392	L.min ⁻¹ , p < 0.001 vs. baseline) and decreased at +23h (9.9 \pm 0.4 L.min ⁻¹ , p = 0.001 vs.
393	baseline). V \square O ₂ was similar at baseline (0.161 ± 0.014 L.min ⁻¹) and increased at +10h (0.236
394	\pm 0.009 L.min ⁻¹ , p = 0.004 vs. baseline). Also V \Box CO ₂ was similar at baseline (0.182 \pm 0.012
395	L.min ⁻¹) yet decreased at +27h (0.0125 \pm 0.017 L.min ⁻¹ , p = 0.018 vs. baseline).
396	

397 *Nocturnal catecholamine excretion.* Nocturnal urine production was similar in all 398 conditions (N_{PL}: 679 ± 375 mL, H_{PL}: 626 ± 223 mL, H_{KE}: 685 ± 321 mL, p = 0.647). Also 399 nocturnal adrenaline (N_{PL}: 5.86 ± 3.66 nmol, H_{PL}: 6.93 ± 4.16 nmol, H_{KE}: 6.60 ± 4.14 nmol, p 400 = 0.305), noradrenaline (N_{PL}: 52.5 ± 22.2 nmol, H_{PL}: 50.3 ± 10.8 nmol, H_{KE}: 56.7 ± 12.4 401 nmol, p = 0.608) and dopamine (N_{PL}: 911 ± 305 nmol, H_{PL}: 795 ± 229 nmol, H_{KE}: 956 ± 350 402 nmol, p = 0.324) excretions were unaffected by the different conditions.

- 403
- 404
- 405

406 **DISCUSSION**

407 Sleeping at (simulated) altitude is increasingly common in athletes either as part of altitude 408 training camps or due to competitions at such altitudes. Earlier studies indicated that, starting 409 from $\sim 2,000$ m, this typically causes an acute reduction in sleep quality (2–10) thereby 410 potentially impairing exercise recovery and readiness to perform. We recently observed that 411 KE ingestion counteracts sleep disruptions induced by late-evening exercise under normoxic 412 conditions (25). Furthermore, KE has also been shown to attenuate hypoxemia, which is 413 considered the primary mechanism underlying hypoxia-induced sleep disturbances (23, 24). 414 Therefore, we investigated whether KE ingestion could counteract sleep disruptions induced 415 by sleeping at altitude (i.e., 3,000m), and impact next day endurance exercise performance. 416 Sleeping at altitude impaired sleep quality as evidenced by a 3% reduction in sleep efficiency, 417 a doubling of WASO and a ~20% reduction in slow wave sleep. These sleep disturbances did 418 not affect performance during a 30-min time-trial the next day, but reduced subsequent heart 419 rate recovery. KE slightly alleviated nocturnal hypoxemia but was unable to negate these 420 sleep disruptions, nor impacted next day exercise performance or subsequent heart rate 421 recovery.

422 Based on the available literature, sleeping at 3,000m altitude is expected to increase WASO 423 (3–7, 9) and potentially decrease slow wave sleep (2, 5, 6, 9, 13), while REM sleep and sleep 424 efficiency generally remain unaffected up to altitudes of ~4,000m (2, 4, 6, 7, 11–13). 425 Although our results on WASO, slow wave sleep and REM are in line with available 426 literature, we observed that even lower simulated altitudes (i.e. 3,000 m) can already elicit a 427 drop in sleep efficiency. As sleep efficiency depicts the time spent asleep over the time spent 428 in bed, with the latter standardized over all sessions, this drop was established by a decreased 429 time asleep through a doubling in WASO. The divergent vs. convergent effects on 430 respectively SE and WASO between our study and earlier studies likely resulted from the fact

21

that we, in contrast to most of the earlier studies, standardized the total time in bed. This is supported by two earlier studies showing that under free-living conditions the observed increase in nocturnal wakefulness upon altitude is at least in part compensated by a ~5% increase in time in bed (6, 7). Nevertheless, this increase in time in bed failed to reach statistical significance in both studies.

436 Increased awakenings upon hypoxia are generally attributed to a hypoxia-induced periodic 437 breathing pattern (5, 31). This phenomenon almost exclusively occurs during NREM sleep 438 and especially during SWS, and causes short awakenings or arousals and disruption of SWS. 439 Our observations indicating that hypoxia decreases SWS but not REM sleep, together with an 440 increased amount of arousals, thus indirectly endorse the important role of periodic breathing 441 in hypoxic sleep impairment. This is further supported by our observation that hypoxia 442 drastically increased the periodic variation of SpO_2 during the night, which is a central 443 hallmark of periodic breathing (29).

444 Sleep disturbances can evoke a myriad of negative effects on processes implicated in 445 exercise performance, training adaptation, and general health. This is evidenced by studies showing that large reductions in sleep quantity (reductions of 2-3 h.night⁻¹ for 1 to 5days) for 446 447 instance increase heart rate during submaximal exercise (14), suppress myofibrillar and 448 sarcoplasmic protein synthesis rates (15, 16), and impair mitochondrial respiratory function 449 (16) and insulin sensitivity (17). Although some studies reported a concomitant drop in both 450 sprint and endurance cycling performance (19, 20), even such large sleep disruptions do not 451 always evoke impairments in exercise performance (14, 18). However, to our knowledge, no 452 data is available on the impact of more subtle sleep disturbances such as those observed in our 453 study.

22

454 The minor sleep disturbances induced by hypoxia in our study did not affect TT_{30} . 455 performance, nor altered resting heart rate, heart rate variability or respiratory parameters the 456 day after. However, the (disrupted) night in hypoxia compromised heart rate recovery after 457 TT_{30} as evidenced by the ~10 bpm higher heart rate in H_{PL} vs. N_{PL} five min after completion 458 of TT_{30} . A reduced or delayed heart rate recovery reflects an impaired vagal activity (32), a 459 strong predictor for morbidity (33), which is generally associated with cardiovascular disease 460 (34) and overtraining (35). This impaired heart rate recovery upon hypoxia may be related to 461 the hypoxia-induced reduction in SWS. Indeed, selective SWS suppression was previously 462 found to disrupt sympathovagal balance by decreasing vagal tone (36) and stimulation of slow 463 waves during sleep improved next day cardiac function, as evidenced through an improved 464 left-ventricular systolic function (37, 38). This indicates that although exercise performance 465 was not affected after one disrupted night, more subtle changes are present which may in the 466 longer term impact exercise recovery, performance or general (cardiovascular) health.

467 In contrast to our hypothesis, KE ingestion did not counteract the hypoxia-induced sleep 468 dysregulations. This conflicts with our earlier data showing that KE intake negated the sleep 469 disruptions induced by strenuous late evening exercise under normoxic conditions (25). A 470 potential explanation for these contrasting observations are the disparate effects of strenuous 471 late evening exercise vs. hypoxia on sleep architecture. Both conditions caused a decrease in 472 sleep efficiency and an increase in WASO. However, while strenuous late evening exercise 473 decreased REM sleep without affecting NREM sleep, hypoxia did not affect REM sleep but 474 decreased SWS. This suggests that ketosis may only beneficially impact sleep when REM is 475 disrupted. This is supported by an earlier study showing that a ketogenic diet improved REM 476 sleep in children with epilepsy (39), a condition typically associated with reduced REM sleep 477 (40). More recent data collected by our group during a 7-week exercise training program 478 confirms this hypothesis as KE only increased REM sleep relative to a placebo group

23

479 whenever REM sleep dropped below baseline values (Robberechts et al., unpublished 480 observations). We previously suggested that the ability of KE to counteract reductions in 481 REM sleep was mediated through an increased dopamine signaling following KE ingestion 482 (41, 42), as dopamine plays an important role in the transition from NREM to REM sleep 483 (43). However, in contrast to our earlier studies, KE intake did not affect nocturnal dopamine 484 excretion in the current study.

485 An important factor in compromised hypoxic sleep is hypoxemia, and subsequent 486 periodic breathing. As described above, periodic breathing induces periods of hypopnea and 487 apnea causing short awakenings especially during SWS (12). As minimal SpO_2 values are 488 closely related to the apneic part of a periodic breathing cycle (44), the observed KE-induced 489 increase (\sim +3%) in minimal SpO₂ and SpO₂ at 40% of sleep duration together with the 490 diminished variance in nocturnal SpO_2 after 2h of sleep suggest a slightly tempered periodic 491 breathing behavior after KE ingestion. However, this effect was likely to small to translate in 492 sleep improvements. As nocturnal respiration was not recorded in the current study, further 493 research is required to identify if KE may impact periodic breathing.

494 On the other hand, hypoxemia activates a wide array of adaptive responses, amongst 495 others establishing the respiratory alkalosis observed in H_{PL}, causing a left-shift of the 496 oxyhemoglobin dissociation curve (ODC) and thus favoring a higher SpO_2 for a given pO_2 . 497 Ingestion of KE, contrarily, established a relative metabolic acidosis in agreement with earlier 498 data (23, 24), thereby pushing a right-shift of the ODC as evidenced by the observed increase 499 in p50. Nevertheless, average nocturnal SpO_2 values were similar after ingestion of KE 500 compared to PL and only after 40% of sleep duration, SpO_2 was higher in KE. This can at 501 least partly be explained by the higher capillary pO_2 values that were observed immediately 502 before sleep, i.e. after 5h in hypoxia, in H_{KE} (56.8 ± 3.4 mmHg) vs. H_{PL} (53.3 ± 4.0 mmHg) 503 thereby compensating the right shift of the OCD. It should however be highlighted that pO_2

24

values were obtained using a capillary sampling method, which might underestimate actual arterial pO_2 .

506 As indicated above, KE increased SpO₂ at 40% of the night, as well as minimal nocturnal 507 SpO_2 , but did not impact SpO_2 at any other timepoint. This is most likely related either to (i) 508 the extent of hypoxemia or (ii) to the specific duration of ketosis or hypoxic exposure. This is 509 supported by our two earlier studies showing that KE attenuated hypoxemia only after ~3-4h 510 of hypoxic exposure and ketosis, and whenever SpO_2 values were below ~82% (23, 24). 511 These requirements were fulfilled at 40% of the night, but not at the other timepoints where 512 we measured SpO_2 . For instance, at +10h participants were in ketosis but had only resided in 513 hypoxia for 2h, while at +23h, participants had resided in hypoxia for 14h however were no 514 longer in ketosis. Furthermore, at the start of the night SpO₂ values were around 90% while 515 during the final part of the night participants were most likely no longer in ketosis (25).

516 Besides hypoxemia, ketone bodies may also affect sleep by altering sympathetic nervous 517 activity. In line with literature (45, 46), hypoxia caused an increase in both resting and 518 nocturnal heart rate, as well as a decrease in all HRV parameters on the first evening of the 519 protocol thereby suggesting a relative dominance of the sympathetic nervous system. Upon 520 waking up however, HF values had recovered but RMSSD and pNN50 values remained 521 depressed. While RMSSD and pNN50 are measures for overall HRV, HF isolates the high-522 frequency component (0.12-0.4 Hz) of the spectrum and entails information on ventilation 523 and respiratory sinus arrhythmias (RSA), a phenomenon explaining fluctuation of HR and 524 HRV together with natural breathing (47–49). As natural breathing is disrupted in hypoxia, 525 both through periodic breathing and consistent hyperventilation, HF was indeed expected to 526 increase (49). While SWS is associated with low heart rate variability in normoxia (50), 527 sympathetic nerve activity is even higher during REM sleep compared to being awake (51). 528 Although the exact relationship between sleep and sympathetic activity remains unclear, it

25

529 cannot be ruled out that this increased sympathetic dominance is linked to the hypoxia530 induced disruption of SWS. However, whether this is either a cause or a consequence remains
531 to be identified.

532 Despite unaffected nocturnal adrenaline and noradrenaline concentrations, KE lowered 533 HRV indices pNN50 and RMSSD upon waking up and increased nocturnal HR. This 534 indicates that, in line with earlier studies performed both in normoxia (25, 52, 53) and 535 hypoxia (23), KE ingestion further promoted sympathetic dominance. In this context, through 536 manipulation of sympathetic activity, ketone bodies may only potentially benefit sleep quality 537 when REM sleep, and not SWS, is disrupted.

538 In conclusion, we observed that a single night of hypoxic exposure (\sim 3,000m altitude) 539 has a detrimental impact on sleep quality, through reduced sleep efficiency, SWS, and 540 increased WASO. While this did not impact next day exercise performance, it hampered post-541 exercise heart rate recovery suggesting that sleeping at (simulated) altitude has minor 542 implications for athlete training management. Contrary to our expectations, ketone ingestion 543 did not mitigate any of these effects. However, we confirmed earlier data showing that KE 544 can alleviate hypoxemia whenever SpO_2 values drop below ~82% and whenever subjects are 545 at least for 3-4h in ketosis. Taken together with our earlier observations, ingestion of ketones 546 as a strategy to improve sleep and recovery appears effective when REM sleep is disrupted 547 (e.g., through late-evening exercise) whereas disruption of NREM sleep (through hypoxic 548 exposure) remains unaffected.

549 ADDITIONAL INFORMATION

550 **Competing interests**

551 The authors declare that they have no competing interests.

552 Author contributions

- 553 All experiments were performed within the Exercise Physiology Research Group and the
- 554 Bakala Academy-Athletic Performance Center at the KU Leuven, Belgium. Conception and
- design of the study: MS, TD and CP. Data collection and/or data analyses: MS, DT, WL, RR,
- 556 MR, TD and CP. Interpretation of the data and manuscript drafting: MS and CP. All authors
- 557 critically revised the manuscript and approved the final version of the manuscript.

558 Funding

- 559 This research was supported by the Research Foundation Flanders (FWO Weave, research
- 560 grant G073522N) and Slovene Research Agency grant (N5-0247). CP is supported by an
- 561 FWO senior postdoctoral research grant (12B0E24N).

562 Acknowledgements

- 563 The authors wish to thank all participants for their dedicated cooperation in this study. We
- also thank Ms. Monique Ramaekers for skillful assistance during the experimental trials.

566 TABLES

	N _{PL}	$\mathbf{H}_{\mathbf{PL}}$	$\mathbf{H}_{\mathbf{KE}}$
SpO ₂ (%)			
Baseline	97.4 ± 1.7	98.5 ± 1.5	98.7 ± 1.3
+10h	98.2 ± 1.1	87 ± 4 §#	88.5 ± 4.5 §#
+23h	98.1 ± 2.1	$89.2 \pm 2.6 \$ #	90.8 ± 3.3 §#
+27h	98.2 ± 1.7	97.9 ± 1.7	98.7 ± 1
HR (bpm)			
Baseline	60.1 ± 6.1	60.7 ± 5.1	57.6 ± 6.1
+10h	65.6 ± 7.8 #	$74.9 \pm 8.6 \$ #	84.8 ± 7 §#*
+23h	51.4 ± 6.3 #	61.3 ± 9.7 §	63.6 ± 8.4 §#
+27h	55.2 ± 6.4 #	56.9 ± 6.9	58.2 ± 7.8
pNN50 (%)			
Baseline	43.4 ± 21.6	45.2 ± 24.8	52.5 ± 23.2
+10h	34.4 ± 23.5	14.1 ± 19.2 §#	4.2 ± 7.6 §#
+23h	59.5 ± 24.9	38.3 ± 21.3 §	22.3 ± 17.1 §*#
+27h	47.4 ± 23.5	50.1 ± 27.0	51.9 ± 23.2
RMSSD (ms)			
Baseline	75.4 ± 41.7	74.2 ± 29.3	86.7 ± 37.4
+10h	62.7 ± 43.1	32.1 ± 22.2 §#	21.3 ± 20.6 §#
+23h	94.2 ± 38.4	70.3 ± 36.2 §	50.8 ± 28.2 §#
+27h	88.9 ± 38.1	96.8 ± 51.6	87.8 ± 38.5
HF (log)			
Baseline	7.42 ± 1.00	7.46 ± 0.72	$7.41 \pm 1.00 $ #
+10h	7.04 ± 1.00	5.67 ± 1.19 §#	4.75 ± 1.56 §#
+23h	7.07 ± 0.99	7.14 ± 0.91	6.46 ± 1.16 *
+27h	7.48 ± 1.34	7.5 ± 1.25	7.62 ± 1.05

567 **Table 1.** Effect of hypoxia (H_{PL} *vs.* N_{PL}) and ketone ester (KE) ingestion (H_{KE} *vs.* H_{PL}) on 568 blood oxygen saturation (SpO₂), heart rate (HR) and heart rate variability (HRV).

During a randomized, cross-over protocol, participants received either ketone ester (KE) or placebo (PL) supplements and spent the night either at a simulated altitude of 3,000m (H_{PL} and H_{KE}) or in normoxia (N_{PL}). Participants' blood oxygen saturation (S_pO_2), heart rate (HR) and heart rate variability (HRV) were assessed at baseline, after 2h in hypoxia/normoxia (+10h), immediately upon waking up in hypoxia/normoxia (+23h) and 2h after returning to normoxia (+27h). Mean values \pm SD (n=11) are shown for SpO₂, HR, the percentage of adjacent NN intervals that differ by more than 50 ms (pNN50), the root mean square of successive differences (RMSSD), and the absolute power of the high-frequency band (HF). §, p < 0.05 *vs.* N_{PL}; *, p < 0.05 *vs.* H_{PL}; #, p < 0.05 *vs.* baseline.

29

	$\mathbf{N}_{\mathbf{PL}}$	$\mathbf{H}_{\mathbf{PL}}$	$\mathbf{H}_{\mathbf{KE}}$
рН			
Baseline	7.409 ± 0.016	7.412 ± 0.013	7.406 ± 0.011
+10h	7.419 ± 0.021	7.438 ± 0.017 §#	7.395 ± 0.016 §#*
+13h	7.414 ± 0.014	7.433 ± 0.018 §#	7.412 ± 0.027
+23h	7.421 ± 0.013 #	7.451 ± 0.026 §#	$7.457 \pm 0.009 $ §#
+27h	7.417 ± 0.015	7.431 ± 0.016 #	7.432 ± 0.018 #
p50 (mmHg)			
Baseline	26.2 ± 0.5	25.9 ± 0.7	25.9 ± 0.9
+10h	25.1 ± 1 #	25.9 ± 0.7	26.8 ± 1.3 §*
+13h	25.8 ± 0.9	25.8 ± 1	25.5 ± 1.4
+23h	25.3 ± 1.3	25 ± 1	24.4 ± 1 §#
+27h	25.6 ± 1.1	25.7 ± 0.6	25.1 ± 1.2
pCO ₂ (mmHg)			
Baseline	41.2 ± 2.2	42 ± 1.8	41.8 ± 1.7
+10h	42.4 ± 1.1	40.9 ± 1.4 §	38 ± 1.2 §*
+13h	42.4 ± 1.6	40 ± 2 §	37.3 ± 2 §*
+23h	41.5 ± 2.2	37 ± 2.1 §	36.7 ± 1.5 §
+27h	42.3 ± 1.7	39.4 ± 1.6 §	39 ± 1.9 §

570 **Table 2.** Effect of hypoxia (H_{PL} *vs.* N_{PL}) and ketone ester (KE) ingestion (H_{KE} *vs.* H_{PL}) on 571 blood acid base balance and capillary blood gases.

During a randomized, cross-over protocol, participants received either ketone ester (KE) or placebo (PL) supplements and spent the night either at a simulated altitude of 3,000m (H_{PL} and H_{KE}) or in normoxia (N_{PL}). Participants' capillary blood was analyzed baseline, after 2h in hypoxia/normoxia (+10h), immediately before sleep (+13h) and upon waking up in hypoxia/normoxia (+23h) and 2h after returning to normoxia (+27h). Capillary blood pH, p50 and pCO₂ were evaluated. §, p < 0.05 *vs.* N_{PL} ; *, p < 0.05 *vs.* H_{PL} ; #, p < 0.05 *vs.* baseline.

573 FIGURES

574 Figure 1. Schematic representation of the experimental protocol that was designed to 575 mimic a live-high train-low (LHTL) strategy. In a double-blind, randomized, crossover 576 design, 11 participants completed three experimental sessions each involving a two-day 577 protocol. On day 1, subjects performed two exercise training sessions [120 min endurance 578 training (ET_{120}) and 80 min high intensity interval training $(HIIT_{80})$ in normoxia followed 579 by a night either in normoxia (N), or at a simulated altitude of 3,000m (H). After each training 580 session and before sleep, participants received either placebo (N_{PL} and H_{PL}) or ketone ester 581 (H_{KE}) supplements. On day 2, exercise performance was evaluated by means of a 30-min all-582 out time trial (TT_{30}) . Sleep quality and architecture were assessed via polysomnography. 583 Physiological measurements were performed in a resting state at baseline, after 2h in hypoxia 584 or equivalent in normoxia, immediately upon waking up and 2h after return to normoxia in 585 order to assess blood oxygen saturation, cerebral and muscular oxygenation status, ventilatory 586 gas exchange, heart rate and heart rate variability. In addition, before every resting 587 measurement, as well as immediately before sleep time, a capillary blood sample was 588 collected for determination of acid-base balance, and blood gasses.



31

591 **Figure 2.** Blood D- β -hydroxybutyrate concentrations ([β HB]) are presented in response 592 to ingestion of ketone ester (KE) or placebo (PL) supplements during experimental sessions 593 including a night (dark grey zone) either in normoxia (NPL, black, open circles) or at a simulated altitude of 3,000m (grey dotted zone; H_{PL} , black and H_{KE} , red full circles). Blood 594 595 $[\beta HB]$ was assessed at baseline, 30min after the morning endurance training (ET₁₂₀; +5.5h) 596 and the afternoon high intensity interval training (HIIT_{80'}; +9h), as well as after 2h in 597 hypoxia/normoxia (+11h), immediately before sleep (+13h) and upon waking up (+23h). 598 Mean (line) \pm SD (whiskers), as well as individual values are shown for n = 11. §, p < 0.05 vs. 599 N_{PL} ; #, p < 0.05 vs. baseline for indicated condition.





602 Figure 3. Data of polysomnographic (PSG) recordings are shown for participants that 603 completed three experimental sessions in which they received either ketone ester (KE) or 604 placebo (PL) supplements. They spent the night either in normoxia (N_{PL}) or at a simulated altitude of 3,000m (H_{PL} and H_{KE}). During the night, participants' sleep was recorded using 605 606 polysomnography (PSG). Mean (bar plots) \pm SD (whiskers), as well as individual values are 607 shown for a) sleep efficiency, b) wakefulness after sleep onset (WASO), c) the amount (#) of 608 arousals per night, and d) sleep onset latency (SOL). Moreover, sleep stage durations are 609 shown for e) slow wave sleep (SWS), f) N1 phase, g) N2 phase, and h) rapid eye movement 610 (REM) sleep. Data are reported for 11 participants and datapoints are connected within each 611 participant. §, $p < 0.05 vs. N_{PL}$.



613 Figure 4. Nocturnal measurements of blood oxygen saturation (SpO₂) and heart rate 614 (HR) are shown for participants that completed three experimental sessions in which they 615 received either ketone ester (KE) or placebo (PL) supplements. They spent the night either in 616 normoxia (N_{PL}) or at a simulated altitude of 3,000m (H_{PL} and H_{KE}). Mean (circles) \pm SD 617 (whiskers) are shown for a) SpO_2 throughout the percentual duration of the night (%). Mean 618 (bar plots) \pm SD (whiskers), as well as individual values are shown for b) average and c) 619 minimal nocturnal $_{SpO2}$ and d) coefficient of variance of SpO2 per hour of the night, as well as 620 e) average and f) minimal nocturnal HR. Data are reported for 11 participants and individual 621 values are connected within each participant. §, p < 0.05 vs. N_{PL}; #, p < 0.05 vs. baseline; ##, p<0.05 vs. baseline for H_{PL} and $H_{KE};$ *, p<0.05 for H_{KE} vs. $H_{PL}.$ 622



34

624 Figure 5. Exercise performance and heart rate data are shown for participants that 625 completed three experimental sessions in which they received either ketone ester (KE) or 626 placebo (PL) supplements during the first day. After spending the night in either in normoxia 627 (N_{PL}) or at a simulated altitude of 3,000m (H_{PL} and H_{KE}), exercise performance was assessed 628 by an all-out 30-min time trial (TT_{30}). Mean (bar plots) \pm SD (a, c, d, whiskers) or mean 629 (horizontal indication) \pm 95% confidence intervals (b, whiskers), as well as individual values 630 are shown for a) mean power output, b) the individual differences in mean power output 631 between all experimental conditions and c) average heart rate (HR) during TT₃₀, and d) HR 632 after 5min of passive recovery. Data are reported for 11 participants and individual values are 633 connected within each participant §, p < 0.05 vs. N_{PL}.



635 **REFERENCES**

- 636 1. Levine BD, Stray-Gundersen J. "Living high-training low": Effect of moderate-
- altitude acclimatization with low-altitude training on performance. *J Appl Physiol* 83:
- 638 102–112, 1997. doi: 10.1152/jappl.1997.83.1.102.
- 639 2. Hoshikawa M, Uchida S, Sugo T, Kumai Y, Hanai Y, Kawahara T. Changes in
- sleep quality of athletes under normobaric hypoxia equivalent to 2,000-m altitude: A
- 641 polysomnographic study. *J Appl Physiol* 103: 2005–2011, 2007. doi:
- 642 10.1152/japplphysiol.00315.2007.
- 643
 3.
 Mizuno K, Asano K, Okudaira N. Sleep and Respiration under Acute Hypobaric

 644
 645
 646
- 644 Hypoxia. Jpn. J. Physiol. 43: 161–175, 1993.
- 645 4. Pedlar C, Whyte G, Emegbo S, Stanley N, Hindmarch I, Godfrey R. Acute sleep
 646 responses in a normobaric hypoxic tent. *Med Sci Sports Exerc* 37: 1075–1079, 2005.
- 647 doi: 10.1249/01.mss.0000171623.52757.0f.
- 5. Reite M, Jackson D, Cahoon RL, Weil J V. Sleep physiology at high altitude.
- *Electroencephalogr Clin Neurophysiol* 38: 463–471, 1975.
- 650 6. Selvamurthy W, Raju VRK, Ranganathan S, Hegde KS, Ray US. Sleep patterns at
- an altitude of 3500 metres. *Int J Biometeorol* 30: 123–135, 1986. doi:
- 652 10.1007/BF02189452.
- 653 7. Zieliński J, Koziej M, Mańkowski M, Sarybaev AS, Tursalieva JS, Sabirov IS,
- 654 Karamuratov AS, Mirrakhimov MM. The quality of sleep and periodic breathing in
- healthy subjects at an altitude of 3200 m. *High Alt Med Biol* 1: 331–336, 2000. doi:
- 656 10.1089/15270290050502408.
- 657 8. Berssenbrugge BYA, Dempsey J, Iber C, Skatrud J, Wilson P. Mechanisms of

36

658 Hypoxia-Induced	Periodic Breathing During	Sleep In Humans.	J Physiol 343: 507–
---------------------	---------------------------	------------------	---------------------

659524, 1983.

660	9.	De Aquino Lemos	V, Antunes	s HKM, Dos Sa	ntos RVT,	Lira FS,	Tufik S,	De Mello
-----	----	-----------------	------------	---------------	-----------	----------	----------	----------

- 661 **MT**. High altitude exposure impairs sleep patterns, mood, and cognitive functions.
- 662 *Psychophysiology* 49: 1298–1306, 2012. doi: 10.1111/j.1469-8986.2012.01411.x.
- 10. **Finnegan TP**, **Abraham P**, **Docherty TB**. Ambulatory monitoring of the
- 664 electroencephalogram in high altitude mountaineers. *Electroencephalogr Clin*
- 665 *Neurophysiol* 60: 220–224, 1985. doi: 10.1016/0013-4694(85)90034-3.

11. Kinsman TA, Gore CJ, Hahn AG, Hopkins WC, Hawley JA, McKenna MJ, Clark

667 SA, Aughey RJ, Townsend NE, Chow CM. Sleep in athletes undertaking protocols of

- exposure to nocturnal simulated altitude at 2650 m. *J Sci Med Sport* 8: 222–232, 2005.
- doi: 10.1016/S1440-2440(05)80013-1.
- Normand H, Barragan M, Benoit O, Bailliart O, Raynaud J. Periodic breathing and
 O2 saturation in relation to sleep stages at high altitude. *Aviat Sp Environ Med* 61:
 229–235, 1990.
- 13. Latshang TD, Lo Cascio CM, Stöwhas A-C, Grimm M, Stadelmann K, Tesler N,

674 Achermann P, Huber R, Kohler M, Bloch KE. Are Nocturnal Breathing, Sleep, and

- 675 Cognitive Performance Impaired at Moderate Altitude (1630-2590 m)? *Sleep* 36:
- 676 1969–1976, 2013.
- 14. Mougin F, Simon-Rigaud ML, Davenne D, Renaud A, Garnier A, Kantelip JP,
- Magnin P. Effects of sleep disturbances on subsequent physical performance. *Eur J Appl Physiol Occup Physiol* 63: 77–82, 1991. doi: 10.1007/BF00235173.
- 680 15. Saner NJ, Lee MJC, Pitchford NW, Kuang J, Roach GD, Garnham A, Stokes T,

681		Phillips SM, Bishop DJ, Bartlett JD. The effect of sleep restriction, with or without
682		high-intensity interval exercise, on myofibrillar protein synthesis in healthy young
683		men. J Physiol 598: 1523–1536, 2020. doi: 10.1113/JP278828.
684	16.	Saner NJ, Lee MJC, Kuang J, Pitchford NW, Roach GD, Garnham A, Genders
685		AJ, Stokes T, Schroder EA, Huo Z, Esser KA, Phillips SM, Bishop DJ, Bartlett
686		JD. Exercise mitigates sleep-loss-induced changes in glucose tolerance, mitochondrial
687		function, sarcoplasmic protein synthesis, and diurnal rhythms. Mol Metab 43: 101110,
688		2021. doi: 10.1016/j.molmet.2020.101110.
689	17.	Sweeney EL, Peart DJ, Kyza I, Harkes T, Ellis JG, Walshe IH. Impaired insulin
690		profiles following a single night of sleep restriction: The impact of acute sprint interval
691		exercise. Int J Sport Nutr Exerc Metab 30: 139-144, 2020. doi:
692		10.1123/IJSNEM.2019-0235.
693	18.	Reilly T , Edwards B . Altered sleep-wake cycles and physical performance in athletes.
694		Physiol Behav 90: 274–284, 2007. doi: 10.1016/j.physbeh.2006.09.017.
695	19.	Chase JD, Roberson PA, Saunders MJ, Hargens TA, Womack CJ, Luden ND.
696		One night of sleep restriction following heavy exercise impairs 3-km cycling time-trial
697		performance in the morning. Appl Physiol Nutr Metab 42: 909-915, 2017. doi:
698		10.1139/apnm-2016-0698.
699	20.	Dean B, Hartmann T, Wingfield G, Larsen P, Skein M. Sleep restriction between
700		consecutive days of exercise impairs sprint and endurance cycling performance. J Sleep
701		Res 32: 1–9, 2023. doi: 10.1111/jsr.13857.
702	21.	Nussbaumer-Ochsner Y, Ursprung J, Siebenmann C, Maggiorini M, Bloch KE.
703		Effect of short-term acclimatization to high altitude on sleep and nocturnal breathing.

704	Sleep 35: 419-423, 201	2. doi: 10.5665/sleep.1708.
	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	p

- 705 22. Weil J V. Sleep at high altitude. *High Alt Med Biol* 5: 180–189, 2004. doi:
- 706 10.1089/1527029041352162.
- 707 23. Stalmans M, Tominec D, Lauriks W, Robberechts R, Poffé C. Exogenous ketosis

attenuates acute mountain sickness and mitigates high-altitude hypoxemia [Online].

709 https://doi.org/10.1101/2023.11.21.23298762.

710 24. Poffé C, Robberechts R, Podlogar T, Kusters M, Debevec T, Hespel P. Exogenous

- 711 ketosis increases blood and muscle oxygenation but not performance during exercise in
- 712 hypoxia. Am J Physiol Integr Comp Physiol 321: R844–R857, 2021. doi:
- 713 10.1152/ajpregu.00198.2021.
- 714 25. Robberechts R, Albouy G, Hespel P, Poffé C. Exogenous Ketosis Improves Sleep
  715 Efficiency and Counteracts the Decline in REM Sleep after Strenuous Exercise. *Med*

716 Sci Sports Exerc 55: 2064–2074, 2023. doi: 10.1249/MSS.00000000003231.

- 717 26. Poffé C, Ramaekers M, Bogaerts S, Hespel P. Bicarbonate Unlocks the Ergogenic
- 718 Action of Ketone Monoester Intake in Endurance Exercise. *Med Sci Sports Exerc* 53:
- 719 431–441, 2020. doi: 10.1249/MSS.00000000002467.
- Poffé C, Wyns F, Ramaekers M, Hespel P. Exogenous Ketosis Impairs 30-min TimeTrial Performance Independent of Bicarbonate Supplementation. *Med Sci Sports Exerc*53: 1068–1078, 2020. doi: 10.1249/MSS.0000000002552.
- 723 28. Nicolas J, King BR, Levesque D, Lazzouni L, Coffey E, Swinnen S, Doyon J,
- 724 Carrier J, Albouy G. Sigma oscillations protect or reinstate motor memory depending
- 725 on their temporal coordination with slow waves. *Elife* 11: 1–26, 2022. doi:
- 726 10.7554/eLife.73930.

727	29.	von Czettritz G, Bax RT, Eckardt T, Springer S, Emmrich P. [Periodic breathing
728		with periodic oxygen variation in infancy]. Wien Med Wochenschr 146: 317-319,
729		1996.
730	30.	Razi NM, DeLauter M, Pandit PB. Periodic breathing and oxygen saturation in
731		preterm infants at discharge. J Perinatol 22: 442-444, 2002. doi:
732		10.1038/sj.jp.7210762.
733	31.	Salvaggio A, Insalaco G, Marrone O, Romano S, Braghiroli A, Lanfranchi P,
734		Patruno V, Donner CF, Bonsignore G. Effects of high-altitude periodic breathing on
735		sleep and arterial oxyhaemoglobin saturation. Eur Respir J 12: 408–413, 1998. doi:
736		10.1183/09031936.98.12020408.
737	32.	Imai K, Sato H, Hori M, Kusuoka H, Ozaki H, Yokoyama H, Takeda H, Inoue M,
738		Kamada T. Vagally mediated heart rate recovery after exercise is accelerated in
739		athletes but blunted in patients with chronic heart failure. J Am Coll Cardiol 24: 1529-
740		1535, 1994. doi: 10.1016/0735-1097(94)90150-3.
741	33.	Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS. Heart Rate
742		Recovery Immediately After Exercise as a Predictor of Mortality. J Cardiopulm
743		<i>Rehabil</i> 20: 131–132, 2000. doi: 10.1097/00008483-200003000-00012.
744	34.	Peçanha T, Silva-Júnior ND, Forjaz CL de M. Heart rate recovery: Autonomic
745		determinants, methods of assessment and association with mortality and cardiovascular
746		diseases. Clin Physiol Funct Imaging 34: 327–339, 2014. doi: 10.1111/cpf.12102.
747	35.	Lamberts RP, Swart J, Capostagno B, Noakes TD, Lambert MI. Heart rate
748		recovery as a guide to monitor fatigue and predict changes in performance parameters.
749		Scand J Med Sci Sport 20: 449-457, 2010. doi: 10.1111/j.1600-0838.2009.00977.x.

750	36.	Tasali E, Leproult R, Ehrmann DA, Van Cauter E. Slow-wave sleep and the risk of
751		type 2 diabetes in humans. Proc Natl Acad Sci USA 105: 1044–1049, 2008. doi:
752		10.1073/pnas.0706446105.
753	37.	Huwiler S, Carro-Domínguez M, Stich F, Sala R, Aziri F, Trippel A, Ryf T,
754		Markendorf S, Niederseer D, Bohm P, Stoll G, Laubscher L, Thevan J, Spengler
755		CM, Gawinecka J, Osto E, Huber R, Wenderoth N, Schmied C, Lustenberger C.
756		Slow waves during deep sleep support cardiac function. Curr Issues Sport Sci 9: 4,
757		2024. doi: 10.36950/2024.2ciss004.
758	38.	Alessandrelli G, Huwiler S, Bernardi G, Carro-domínguez M, Stich F.
759		Cardiovascular responses to natural and auditory evoked slow waves predict post-sleep
760		cardiac function
761	39.	Hallböök T, Lundgren J, Rosén I. Ketogenic diet improves sleep quality in children
762		with therapy-resistant epilepsy. Epilepsia 48: 59-65, 2007. doi: 10.1111/j.1528-
763		1167.2006.00834.x.
764	40.	Sadak U, Honrath P, Ermis U, Heckelmann J, Meyer T, Weber Y, Wolking S.
765		Reduced REM sleep: a potential biomarker for epilepsy – a retrospective case-control
766		study. Seizure 98: 27-33, 2022. doi: 10.1016/j.seizure.2022.03.022.
767	41.	Church WH, Adams RE, Wyss LS. Ketogenic diet alters dopaminergic activity in the
768		mouse cortex. Neurosci Lett 571: 1-4, 2014. doi: 10.1016/j.neulet.2014.04.016.
769	42.	Robberechts R, Poffé C. Defining ketone supplementation: the evolving evidence for
770		post-exercise ketone supplementation to improve recovery and adaptation to exercise.
771		Am J Physiol Physiol, 2023. doi: 10.1152/ajpcell.00485.2023.
772	43.	Hasegawa E, Miyasaka A, Sakurai K, Cherasse Y, Li Y, Sakurai T. Rapid eye

773		movement sleep is initiated by basolateral amygdala dopamine signaling in mice.
774		Science (80-) 375: 994–1000, 2022. doi: 10.1126/science.abl6618.
775	44.	West JB, Peters RM, Aksnes G, Maret KH, Milledge JS, Schoene RB. Nocturnal
776		periodic breathing at altitudes of 6,300 and 8,050 m. J Appl Physiol 61: 280–287, 1986.
777		doi: 10.1152/jappl.1986.61.1.280.
778	45.	Bernardi L, Passino C, Spadacini G, Calciati A, Robergs R, Greene R, Martignoni
779		E, Anand I, Appenzeller O. Cardiovascular autonomic modulation and activity of
780		carotid baroreceptors at altitude. Clin Sci 95: 565–573, 1998. doi: 10.1042/cs0950565.
781	46.	Guyenet PG. Neural structures that mediate sympathoexcitation during hypoxia.
782		Respir Physiol 121: 147–162, 2000. doi: 10.1016/S0034-5687(00)00125-0.
783	47.	Novak V, Novak P, De Champlain, J, Le Blanc R, Martin R, Nadeau R. Influence
784		of Respiration on Heart Rate and Blood Pressure Fluctuations. J Physiol 74: 617-626,
785		1993. doi: 10.1201/b15277-5.
786	48.	Brown TE, Beightol LA, Koh J, Eckberg DL. Important influence of respiration on
787		human R-R interval power spectra is largely ignored. J Appl Physiol 75: 2310–2317,
788		1993. doi: 10.1152/jappl.1993.75.5.2310.
789	49.	Morales JF, Deviaene M, Milagro J, Testelmans D, Buyse B, Willems R, Orini M,
790		Van Huffel S, Bailon R, Varon C. Evaluation of Methods to Characterize the Change
791		of the Respiratory Sinus Arrhythmia with Age in Sleep Apnea Patients
792	50.	Brandenberger G, Ehrhart J, Piquard F, Simon C. Inverse coupling between
793		ultradian oscillations in delta wave activity and heart rate variability during sleep. Clin
794		Neurophysiol 112: 992–996, 2001. doi: 10.1016/S1388-2457(01)00507-7.

## 795 51. Somers VK, Dyken ME, Mark AL, Abboud FM. Sympathetic-Nerve Activity

- During Sleep in Normal Subjects. *N Engl J Med* 328: 303–307, 1993.
- 797 52. Kolanowski J, Young JB, Landsberg L. Stimulatory influence of d(-)3-
- hydroxybutyrate feeding on sympathetic nervous system activity in the rat. *Metabolism*
- 799 43: 180–185, 1994.
- 800 53. Robberechts R, Poffé C, Hespel P. Exogenous ketosis suppresses diuresis and atrial
- 801 natriuretic peptide during exercise. *J Appl Physiol* : 449–460, 2022. doi:
- 802 10.1152/japplphysiol.00061.2022.

803